Preceptorship 2024

March 14-16, Rydges Melbourne

PSMA Theranostics: Precision Oncology in Practice

The second ProsTIC Preceptorship "Precision Oncology in Practice” ran from the 14 - 16 March 2024 at the Rydges Melbourne.

365 Delegates from 27 countries including Argentina, Australia, Brazil, Canada, China, Colombia, Denmark, Germany, India, Indonesia, Iran, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, Philippines, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand & The United States attended the 2024 Preceptorship. The Preceptorship would not have been possible without the generous contributions from our Sponsors & Supporters.

This immersive, multidisciplinary course brought together professionals across nuclear medicine, medical oncology, radiation oncology, and urology who are seeking to advance their skills and knowledge in the rapidly evolving field of theranostics.

The session recordings for the ProsTIC Preceptorship will be made available from mid-2024 onward via the ProsTIC TV YouTube channel: https://www.youtube.com/@ProsTICTV
The first session is already LIVE, with more to be uploaded each week.

Please subscribe to our YouTube channel and turn on post notifications to ensure you don’t miss an upload.

Sincere thanks to everyone that contributed to making this meeting a wonderful success.

Professor Michael Hofman

Chair, ProsTIC Preceptorship 2024

Director, Prostate Cancer Theranostics and Imaging Centre of Excellence

ProsTIC 2024 Organising Committee

  • Prof. Declan Murphy

    Director of Genitourinary Oncology at Peter MacCallum Cancer Centre

  • Ms. Annette Van Der Heyden

    Program Manager, ProsTIC

  • Ms. Elizabeth Medhurst

    PSMA Theranostics Nurse Consultant, ProsTIC

  • Dr James Buteau

    Clinical Nuclear Medicine Fellow, PhD Candidate, ProsTIC

  • Ms. Shae Collins

    Senior Administration Coordinator, ProsTIC

  • Mr. David Chen

    BMedSc(Hons)/MD research student, ProsTIC

At ProsTIC, we have three aims

  1. Accelerate clinical trial research: Expand the portfolio of clinical trials investigating the use of PSMA PET imaging and therapy targeting areas of high-impact need that are not currently being addressed. 

  2. Education and Leadership: Establish a global hub of excellence to educate doctors, scientists, patients and the community about the application and benefits of this new technology. 

  3. Discovery research: Further investigate next generation targets, develop biomarkers to predict and monitor response to PSMA therapy, optimise new combinations with PSMA therapy in pre-clinical models, explore the use of radio-guided surgery and artificial intelligence image interpretation.